Abdulrahman Alwaki, MD
Clinical Neurophysiology · Houston, TXNPI 1538457510
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,032 of the $2,691 with a category attached, or 75.5%. 6 manufacturers reported payments, led by DIXI Medical USA Corp at 57.7% of the total.
Across 10 payments — averaging $269.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- DIXI Medical USA Corp$2K
- Neuropace, Inc.$727
- Medtronic$294
- Boston Scientific$66
- Jazz Pharmaceuticals Inc.$27
- AbbVie$25
Across 15 payments — averaging $3090.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$46K
What the payments were for
- Travel & lodging$65924%
- Food & beverage$2,03276%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| DIXI Medical USA Corp | 2 | $1,552 |
| Neuropace, Inc. | 3 | $727 |
| Medtronic(2 entities) | 2 | $294 |
| Boston Scientific | 1 | $66 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| AbbVie | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,691 in reported general payments places this provider in the 55th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 27 | $843 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $841 |
| Lamotrigine | 16 | $228 |
| Topiramate | 20 | $165 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Houston
- Thy NguyenHouston$133K
- Nora Vanegas ArroyaveHouston$82K
- Samden LhatooHouston$66K
- Omotola HopeHouston$63K
- Hina DaveHouston$48K
- Monika UmmatHouston$36K
- Sudha TallavajhulaHouston$14K
- Victor LevinHouston$10K
- Shaun SmartHouston$9K
- Kristin BrownHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.